Pasi A. Jänne, MD, PhD

Pasi A. Jänne, MD, PhD, is senior vice president for Translational Medicine, director of the Belfer Center for Applied Cancer Science, director of the Chen-Huang Center for EGFR Mutant Lung Cancers, a senior physician, and the David M. Livingston, MD, Chair at Dana-Farber Cancer Institute; as well as a professor of medicine at Harvard Medical School

Articles

Dr Jänne on Second-Line Treatment Evolutions in EGFR-Mutated NSCLC

July 25th 2025

Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLC

April 10th 2024

Dr Jänne on the FDA Approval of Osimertinib Plus Chemotherapy in EGFR+ mNSCLC

February 16th 2024

Pasi A. Jänne, MD, PhD, discusses the FDA approval of osimertinib plus chemotherapy in patients with EGFR-mutant locally advanced or metastatic NSCLC.

Dr Jänne on the Investigation of RMC-6291 in KRAS G12C-Mutated Solid Tumors

November 7th 2023

Pasi A. Jänne, MD, PhD, discusses the mechanism of action of the novel KRAS G12C RAS(ON) inhibitor RMC-6291, which is being evaluating for the treatment of patients with KRAS-mutated solid tumors.

Looking at Novel Treatments in Lung and Genitourinary Cancers From ESMO 2023: Drs Janne and Bastos

October 21st 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr Jänne on Trastuzumab Deruxtecan in HER2-Mutant NSCLC

September 22nd 2023

Pasi A. Jänne, MD, PhD, discusses key findings from the primary analysis of the phase 2 DESTINY-Lung02 trial in patients with HER2-mutant non–small cell lung cancer.

Dr Jänne on Osimertinib Plus Platinum-Based Chemotherapy in EGFR-Mutant NSCLC

September 11th 2023

Pasi A. Jänne, MD, PhD, discusses findings from the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer.

Dr Jänne on the FLAURA2 and MARIPOSA Trials of Single-Agent Osimertinib in EGFR-Mutant NSCLC

August 9th 2023

Pasi A. Jänne, MD, PhD, discusses key trials evaluating the efficacy of single-agent osimertinib in patients with metastatic EGFR-mutated non–small cell lung cancer.

Dr Jänne on BL-B01D1 in NSCLC and Other Solid Tumors

June 21st 2023

Pasi A. Jänne, MD, PhD, discusses findings from a first-in-human phase 1 trial investigating the EGFRxHER3 bispecific antibody-drug conjugate BL-B01D1 in patients with advanced non–small cell lung cancer and other advanced solid tumors.

Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC

February 10th 2021

Pasi A. Jänne, MD, PhD, discusses the rationale for exploring mobocertinib in EGFR exon 20–mutated non–small cell lung cancer.

Dr. Jänne on Biomarker Results From a Study of AZD9291

September 9th 2015

Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, discusses biomarker results from the AURA study of AZD9291.

x